Blockchain Registration Transaction Record

NanoViricides' NV-387 Gets Orphan Drug Designation for Measles

NanoViricides' NV-387 receives FDA Orphan Drug Designation for measles, offering tax credits and market exclusivity. Learn about this broad-spectrum antiviral and its potential impact.

This news matters because measles outbreaks are on the rise globally, and there are currently no approved antiviral treatments specifically for measles. The Orphan Drug Designation for NV-387 not only accelerates its development through FDA incentives but also highlights a potential breakthrough in addressing a serious public health threat. For investors, this designation could significantly enhance the drug's commercial prospects and the company's valuation. For patients, it offers hope for a targeted therapy against a dangerous and highly contagious disease.